Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 46
Filtrar
1.
J Mass Spectrom ; 59(6): e5031, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38726684

RESUMEN

Managing ocular microbial infections typically requires pharmacotherapy using antibiotic eye drops, such as moxifloxacin hydrochloride (MFX), combined with an antifungal agent like amphotericin B (AB). We carried out and validated an LC-MS/MS assay to quantify these compounds in rabbit tear fluid in order to look into the pharmacokinetics of these two drugs. We employed a protein precipitation technique for the extraction of drugs under examination. A Waters Symmetry C18 column was used to separate the analytes and internal standard. The composition of the mobile phase was like (A) 0.1% v/v formic acid in water and (B) methanol. The detection of MFX and AB was accomplished through the utilization of positive ion electrospray ionization under multiple reaction monitoring mode. The linearity curves for both analytes exhibited an acceptable trendline across a concentration range of 2.34-300 ng/mL for MFX and 7.81-1000 ng/mL for AB in surrogate rabbit tear fluid. The lower limit of quantitation for MFX was 2.34 ng/mL, while for AB, it was 7.81 ng/mL. The approach was strictly validated, encompassing tests of selectivity, linearity (with r2 > 0.99), precision, accuracy, matrix effects, and stability. Consequently, we employed this method to evaluate the pharmacokinetics profiles of MFX and AB in rabbit tear fluid following single topical doses.


Asunto(s)
Moxifloxacino , Espectrometría de Masas en Tándem , Lágrimas , Conejos , Animales , Espectrometría de Masas en Tándem/métodos , Lágrimas/química , Moxifloxacino/farmacocinética , Moxifloxacino/análisis , Reproducibilidad de los Resultados , Anfotericina B/farmacocinética , Anfotericina B/análisis , Límite de Detección , Antiinfecciosos/farmacocinética , Antiinfecciosos/análisis , Cromatografía Liquida/métodos , Soluciones Oftálmicas/farmacocinética , Modelos Lineales , Cromatografía Líquida con Espectrometría de Masas
2.
Paediatr Drugs ; 24(2): 163-173, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-35284983

RESUMEN

BACKGROUND/OBJECTIVE: Moxifloxacin is a fluoroquinolone that is commonly used in adults, but not children. Certain clinical situations compel pediatric clinicians to use moxifloxacin, despite its potential for toxicity and limited pharmacokinetics (PK) data. Our objective was to further characterize the pharmacokinetics of moxifloxacin in children. METHODS: We performed an opportunistic, open-label population PK study of moxifloxacin in children < 18 years of age who received moxifloxacin as part of standard care. A set of structural PK models and residual error models were explored using nonlinear mixed-effects modeling. Covariates with known biological relationships were investigated for their influence on PK parameters. RESULTS: We obtained 43 moxifloxacin concentrations from 14 participants who received moxifloxacin intravenously (n = 8) or orally (n = 6). The dose of moxifloxacin was 10 mg/kg daily in participants ≤ 40 kg and 400 mg daily in participants > 40 kg. The population mean clearance and mean volume of distribution were 18.2 L/h and 167 L, respectively. The oral absorption was described by a first-order process. The estimated extent of oral bioavailability was highly variable (range 20-91%). Total body weight was identified as a covariate on clearance and volume of distribution, and substantially reduced the random unexplained inter-individual variability for both parameters. No participants experienced suspected serious adverse reactions related to moxifloxacin. CONCLUSION: These data add to the existing literature to support use of moxifloxacin in children in certain situations; however, further prospective studies on the safety and efficacy of moxifloxacin are needed.


Asunto(s)
Moxifloxacino , Adulto , Niño , Humanos , Moxifloxacino/farmacocinética , Estudios Prospectivos
3.
J Bone Joint Surg Am ; 104(1): 49-54, 2022 01 05.
Artículo en Inglés | MEDLINE | ID: mdl-34731098

RESUMEN

BACKGROUND: Peri and postoperative antibiotics are key adjuvant treatment tools in the management of periprosthetic joint infection (PJI). The aim of this study was to evaluate the effect of rifampicin on the area under the moxifloxacin concentration-time curve from 0 to 24 hours (AUC0-24) in the synovial fluid of the knee joint, tibial bone, and adjacent subcutaneous tissue under steady-state conditions using microdialysis in a porcine model. METHODS: Twenty female pigs were randomized to receive oral treatment with moxifloxacin monotherapy (Group A, n = 10) of 400 mg once daily for 3 days or a combination therapy (Group B, n = 10) of 400 mg of moxifloxacin once daily for 3 days and 450 mg of rifampicin twice daily for 7 days. Microdialysis was used for sampling the synovial fluid of the knee joint, tibial cancellous and cortical bone, and adjacent subcutaneous tissues. Plasma samples were taken as a reference. Measurements were obtained for 24 hours. RESULTS: Coadministration of moxifloxacin and rifampicin resulted in reductions of the moxifloxacin AUC0-24 in all targeted tissue compartments by 67% to 85% (p < 0.05). The corresponding change in plasma was 20% (p = 0.49). For both groups, the tissue penetration (the ratio of tissue free fraction AUC0-24 to plasma free fraction AUC0-24 [fAUCtissue/fAUCplasma]) was incomplete in all investigated compartments. The highest moxifloxacin tissue penetration was in the knee joint synovial fluid: 0.59 (Group A) and 0.24 (Group B). The lowest tissue penetration was in the cortical bone: 0.17 (Group A) and 0.03 (Group B). CONCLUSIONS: We found a significant reduction of the moxifloxacin concentration, expressed as the AUC0-24, in tissues relevant to acute PJI treatment when coadministered with rifampicin. CLINICAL RELEVANCE: The concentrations within the targeted tissue compartments were reduced significantly more than the concentrations in plasma, which may be particularly important as plasma concentrations are used in clinical practice to assess moxifloxacin treatment sufficiency.


Asunto(s)
Articulación de la Rodilla , Moxifloxacino , Rifampin , Tejido Subcutáneo , Tibia , Animales , Femenino , Administración Oral , Área Bajo la Curva , Quimioterapia Combinada , Articulación de la Rodilla/metabolismo , Microdiálisis , Moxifloxacino/administración & dosificación , Moxifloxacino/farmacocinética , Infecciones Relacionadas con Prótesis/prevención & control , Rifampin/administración & dosificación , Rifampin/farmacocinética , Tejido Subcutáneo/metabolismo , Porcinos , Tibia/metabolismo
4.
J Clin Pharmacol ; 62(3): 385-396, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34554580

RESUMEN

Moxifloxacin has an important role in the treatment of tuberculosis (TB). Unfortunately, coadministration with the cornerstone TB drug rifampicin results in suboptimal plasma exposure. We aimed to gain insight into the moxifloxacin pharmacokinetics and the interaction with rifampicin. Moreover, we provided a mechanistic framework to understand moxifloxacin pharmacokinetics. We developed a physiologically based pharmacokinetic model in Simcyp version 19, with available and newly generated in vitro and in vivo data, to estimate pharmacokinetic parameters of moxifloxacin alone and when administered with rifampicin. By combining these strategies, we illustrate that the role of P-glycoprotein in moxifloxacin transport is limited and implicate MRP2 as transporter of moxifloxacin-glucuronide followed by rapid hydrolysis in the gut. Simulations of multiple dose area under the plasma concentration-time curve (AUC) of moxifloxacin (400 mg once daily) with and without rifampicin (600 mg once daily) were in accordance with clinically observed data (predicted/observed [P/O] ratio of 0.87 and 0.80, respectively). Importantly, increasing the moxifloxacin dose to 600 mg restored the plasma exposure both in actual patients with TB as well as in our simulations. Furthermore, we extrapolated the single dose model to pediatric populations (P/O AUC ratios, 1.04-1.52) and the multiple dose model to children with TB (P/O AUC ratio, 1.51). In conclusion, our combined approach resulted in new insights into moxifloxacin pharmacokinetics and accurate simulations of moxifloxacin exposure with and without rifampicin. Finally, various knowledge gaps were identified, which may be considered as avenues for further physiologically based pharmacokinetic refinement.


Asunto(s)
Antituberculosos/farmacología , Moxifloxacino/farmacocinética , Rifampin/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/efectos de los fármacos , Adulto , Antituberculosos/farmacocinética , Área Bajo la Curva , Niño , Quimioterapia Combinada , Glucuronosiltransferasa/metabolismo , Células HEK293 , Humanos , Modelos Biológicos , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos/metabolismo
5.
AAPS PharmSciTech ; 22(5): 195, 2021 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-34184117

RESUMEN

Microbial keratitis (MK) is a vision-threatening disease and the fourth leading cause of blindness worldwide. In this work, we aim to develop moxifloxacin (MXN)-loaded chitosan-based cationic mucoadhesive polyelectrolyte nanocapsules (PENs) for the effective treatment of MK. PENs were formulated by polyelectrolyte complex coacervation method and characterized for their particle size, surface charge, morphology, mucoadhesive property, in-vitro and ex-vivo release, ocular tolerance, and antimicrobial efficacy studies. The pharmacodynamic study was conducted on rabbit eye model of induced keratitis and it is compared with marketed formulation (MF). Developed PENs showed the size range from 230.7 ± 0.64 to 249.0 ± 0.49 nm and positive surface charge, spherical shape along with appropriate physico-chemical parameters. Both in-vitro and ex-vivo examination concludes that PENs having more efficiency in sustained release of MXN compared to MF. Ocular irritation studies demonstrated that no corneal damage or ocular irritation. The in-vivo study proved that the anti-bacterial efficacy of PENs was improved when compared with MF. These results suggested that PENs are a feasible choice for MK therapy because of their ability to enhance ocular retention of loaded MXN through interaction with the corneal surface of the mucous membrane.


Asunto(s)
Desarrollo de Medicamentos/métodos , Queratitis/tratamiento farmacológico , Moxifloxacino/síntesis química , Nanocápsulas/química , Polielectrolitos/síntesis química , Animales , Antibacterianos/administración & dosificación , Antibacterianos/síntesis química , Antibacterianos/farmacocinética , Embrión de Pollo , Córnea/efectos de los fármacos , Córnea/metabolismo , Córnea/microbiología , Cabras , Queratitis/metabolismo , Queratitis/microbiología , Moxifloxacino/administración & dosificación , Moxifloxacino/farmacocinética , Nanocápsulas/administración & dosificación , Polielectrolitos/administración & dosificación , Polielectrolitos/farmacocinética , Conejos
6.
Int J Biol Macromol ; 182: 2087-2096, 2021 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-34087298

RESUMEN

The aim of our study was to prepare nanoparticles of disulfide bridged thiolated chitosan and eudragit RS100 using the air oxidation method for controlled drug delivery. The developed nanoparticles were characterized by FTIR, DSC, TGA, zeta sizer, zeta potential, SEM and 1H NMR. The loading, entrapment efficiency and in-vitro release of moxifloxacin from nanoparticles was determined. Toxicity was studied using Caco-2 cell line and pharmacokinetics of moxifloxacin from the developed nanoparticles was studied in albino rats. The FTIR analysis showed no chemical interaction of the drug with the thiolated polymers. The DSC and TGA showed the thermal stability of nanoparticles. The average particle size of nanoparticles was 87 nm, zeta potential of NTC3 was ± 19 and SEM showed the spherical shape of nanoparticles. The 1H NMR spectra confirmed the structure of thiolated chitosan and eudragit RS100. The loading, encapsulation efficiency and release of moxifloxacin from NTC3 were 100.3%, 89.67% and 88.49% respectively. The nanoparticles in culture medium did not affect the viability of Caco-2 cells. The NTC3 formulation showed a greater bioavailability of moxifloxacin compared to the reference formulation. The study reports a convenient and effective way to prepare a chitosan and eudragit RS100 based drug delivery system with a controlled release pattern.


Asunto(s)
Resinas Acrílicas/química , Quitosano/química , Disulfuros/química , Sistemas de Liberación de Medicamentos , Moxifloxacino/farmacología , Nanopartículas/química , Compuestos de Sulfhidrilo/química , Animales , Células CACO-2 , Rastreo Diferencial de Calorimetría , Supervivencia Celular/efectos de los fármacos , Preparaciones de Acción Retardada/farmacología , Liberación de Fármacos , Humanos , Hidrodinámica , Cinética , Moxifloxacino/farmacocinética , Tamaño de la Partícula , Espectroscopía de Protones por Resonancia Magnética , Ratas , Espectroscopía Infrarroja por Transformada de Fourier , Electricidad Estática , Termogravimetría
7.
Sci Rep ; 11(1): 2605, 2021 01 28.
Artículo en Inglés | MEDLINE | ID: mdl-33510326

RESUMEN

To investigate the effect of simulated weightlessness on the pharmacokinetics of orally administered moxifloxacin and the antacid Maalox or the antidiarrheal Pepto-Bismol using a tail-suspended (TS) rat model of microgravity. Fasted control and TS, jugular-vein-cannulated, male Sprague-Dawley rats received either a single 5 mg/kg intravenous dose or a single 10 mg/kg oral dose of moxifloxacin alone or with a 0.625 mL/kg oral dose of Maalox or a 1.43 mL/kg oral dose of Pepto-Bismol. Plasma concentrations of moxifloxacin were measured by HPLC. Pharmacokinetic data were analyzed using WinNonlin. Simulated weightlessness had no effect on moxifloxacin disposition after intravenous administration but significantly decreased the extent of moxifloxacin oral absorption. The coadministration of moxifloxacin with Maalox to either control or TS rats caused significant reductions in the rate and extent of moxifloxacin absorption. In contrast, the coadministration of moxifloxacin with Pepto-Bismol to TS rats had no significant effect on either the rate or the extent of moxifloxacin absorption. These interactions showed dose staggering when oral administrations of Pepto-Bismol and moxifloxacin were separated by 60 min in control rats but not in TS rats. Dose staggering was more apparent after the coadministration of Maalox and moxifloxacin in TS rats.


Asunto(s)
Antibacterianos/farmacocinética , Moxifloxacino/farmacocinética , Ingravidez/efectos adversos , Administración Oral , Hidróxido de Aluminio/farmacocinética , Animales , Antiácidos/farmacocinética , Antidiarreicos/farmacocinética , Bismuto/farmacocinética , Combinación de Medicamentos , Interacciones Farmacológicas , Hidróxido de Magnesio/farmacocinética , Masculino , Compuestos Organometálicos/farmacocinética , Ratas , Ratas Sprague-Dawley , Salicilatos/farmacocinética , Simulación de Ingravidez
8.
J Pharmacokinet Pharmacodyn ; 48(2): 203-211, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33512637

RESUMEN

Concentration-QTc (C-QTc) modeling is being increasingly used in phase 1 studies. For studies without a placebo arm (single arm studies), the scientific whitepaper by Garnett et al. ( https://doi.org/10.1007/s10928-017-9558-5 ) states that time-matched baseline adjustments may minimize the effect of diurnal variation in QTc intervals, and categorical time effects are not needed in the model. However, how diurnal variations can be accounted for when only pre-dose baselines are available is unclear. This research investigates whether including categorical time effects in the model can adjust diurnal variation in single arm studies with pre-dose baselines, where QTc prolongation is evaluated at a concentration of interest based on ΔQTc at 24 h and ΔΔQTc (a model-derived difference in ΔQTc from concentration zero). To understand the operating characteristics for the models with and without categorical time effects, simulations were conducted under various scenarios considering oncology early phase studies. When the C-QTc relationship is linear, models without categorical time effects provided biased estimates for model parameters and inflated or decreased false negative rates (FNRs) depending on the pattern of diurnal variations in QTc intervals, whereas models with categorical time effects caused no biases and controlled the FNRs. For non-linear C-QTc relationships, ΔΔQTc estimations made using the model with categorical time effects were not robust. Thus, for single arm studies where only pre-dose baselines are available, we recommend collecting QTc measurements at 24 h and estimating ΔQTc at a concentration of interest at 24 h using the C-QTc model with categorical time effects.


Asunto(s)
Electrocardiografía/efectos de los fármacos , Síndrome de QT Prolongado/diagnóstico , Ensayos Clínicos Fase I como Asunto , Simulación por Computador , Estudios Cruzados , Conjuntos de Datos como Asunto , Relación Dosis-Respuesta a Droga , Voluntarios Sanos , Humanos , Síndrome de QT Prolongado/inducido químicamente , Modelos Biológicos , Moxifloxacino/administración & dosificación , Moxifloxacino/efectos adversos , Moxifloxacino/farmacocinética , Proyectos de Investigación , Factores de Tiempo
9.
Clin Pharmacol Ther ; 109(4): 1045-1054, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-32617960

RESUMEN

To prevent antibiotic-induced perturbations on gut microbiota, DAV132, a novel colon-targeted adsorbent, which sequesters antibiotic residues in the lower gastrointestinal tract, was developed. We built an integrated pharmacological model of how DAV132 reduces fecal free moxifloxacin and preserves gut microbiota. We used plasma and fecal free moxifloxacin concentrations, and Shannon diversity index from 16S ribosomal RNA gene metagenomics analysis of fecal microbiota, of 143 healthy volunteers assigned randomly to receive moxifloxacin only, or with 10 DAV132 dose regimens, or to a control group. We modeled reduced fecal moxifloxacin concentrations using a transit model for DAV132 kinetics and a Michaelis-Menten model with an effect of the amount of activated charcoal on adsorption efficacy. Changes in moxifloxacin-induced perturbations on gut microbiota diversity were then quantified through a turnover model with the Emax model. With the developed model, the efficiency of pharmacokinetic antagonism and its consequences on gut microbiota diversity were quantified.


Asunto(s)
Colon/efectos de los fármacos , Heces/química , Microbioma Gastrointestinal/efectos de los fármacos , Moxifloxacino/farmacocinética , Adolescente , Adsorción/fisiología , Adulto , Relación Dosis-Respuesta a Droga , Femenino , Voluntarios Sanos , Humanos , Masculino , Metagenómica , Persona de Mediana Edad , Modelos Biológicos , Moxifloxacino/administración & dosificación , ARN Ribosómico 16S/genética , Adulto Joven
10.
Biomed Pharmacother ; 130: 110619, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32795925

RESUMEN

PURPOSE: To elucidate the relationship between antofloxacin (AT) plasma concentration and QT interval prolongation, compare the effects of different correction and analytical methods on conclusions, and estimate the possible false-positive rate in thorough QT (TQT) studies. METHODS: Twenty-four healthy Chinese volunteers from a four-period crossover TQT study orally received 200 mg/d AT, 400 mg/d AT, 400 mg/d moxifloxacin, and a placebo in a random order for 5 d for each. QT interval samples were collected on d 1 and d 5. Population models were established describing the relationship between QT and AT concentration. The yardstick from ICH E14 guidelines was used to measure the effect of drugs on QT prolongation both in biostatistical and modeling analyses. A possible false-positive rate was estimated by constructing a 1000-time bootstrap to obtain the rate-of-difference values between d 1 and d 5 over 5 ms in the placebo period. RESULTS: In the modeling analysis, the QT prolongation estimate at the mean maximal concentration of AT (4.51 µg/mL) was 3.84 ms, and its upper bound of the one-sided 95 % CI was 7.04 ms, which showed a negative effect on QT interval prolongation. The estimation for the false-positive rate was 31 % in this study. CONCLUSION: The effect of AT on QT interval prolongation may not have been significant at the dosage of 400 mg. Baseline and placebo adjustments were necessary in TQT studies. Population modeling has demonstrated clear superiority in making full use of data to accurately analyze the relationship between drugs and QT intervals.


Asunto(s)
Antibacterianos/efectos adversos , Antibacterianos/farmacocinética , Síndrome de QT Prolongado/inducido químicamente , Ofloxacino/análogos & derivados , Adulto , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Electrocardiografía/efectos de los fármacos , Reacciones Falso Positivas , Femenino , Voluntarios Sanos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Modelos Estadísticos , Moxifloxacino/efectos adversos , Moxifloxacino/farmacocinética , Ofloxacino/efectos adversos , Ofloxacino/farmacocinética , Adulto Joven
11.
J Clin Pharmacol ; 60(11): 1483-1495, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32488885

RESUMEN

This study evaluated the effect of 3 doses of a trazodone hydrochloride 6% oral drops solution on the QT interval of healthy volunteers. Subjects were randomly assigned to receive a single dose of trazodone 20 mg, 60 mg, and 140 mg, moxifloxacin 400 mg, and trazodone-matched placebo in 5 periods separated by 7-day washouts, according to a double-blind, crossover study design. Subjects were monitored continuously, and triplicate ECGs were extracted from baseline (predose) until 24 hours postdose. Blood samples for trazodone and moxifloxacin analyses were collected at the same time points. The concentration-QTc relationship assessed on placebo-adjusted change from baseline for Fridericia-corrected QT (ΔΔQTcF) was the primary end point. ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20-, 60-, and 140-mg doses were observed at the corresponding trazodone peak plasma concentrations. The upper bound of the 90%CI exceeded 10 ms for the 60- and the 140-mg doses. Time-matched analysis results were in line with these findings. No significant trazodone effect on heart rate or PR or QRS intervals and no clinically significant new morphological changes were present. In this moxifloxacin-validated ECG trial, trazodone had a modest, dose-dependent effect on cardiac repolarization, with no QTc prolongation observed with the 20-mg dose and an effect exceeding the values set in E14 guideline with the 60- and 140-mg doses. The effect on cardiac repolarization is unlikely to represent a clinical risk for ventricular proarrhythmia, but caution should be used with concomitant use of other medications that prolong QT or increase trazodone exposure.


Asunto(s)
Antidepresivos de Segunda Generación/administración & dosificación , Antidepresivos de Segunda Generación/farmacología , Sistema de Conducción Cardíaco/efectos de los fármacos , Síndrome de QT Prolongado/inducido químicamente , Trazodona/administración & dosificación , Trazodona/farmacología , Administración Oral , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antibacterianos/farmacocinética , Antidepresivos de Segunda Generación/efectos adversos , Antidepresivos de Segunda Generación/farmacocinética , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Voluntarios Sanos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Moxifloxacino/administración & dosificación , Moxifloxacino/efectos adversos , Moxifloxacino/farmacocinética , Soluciones Farmacéuticas , Trazodona/efectos adversos , Trazodona/farmacocinética , Adulto Joven
12.
J Pharmacol Sci ; 143(4): 272-280, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32499095

RESUMEN

We analyzed the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action using the chronic atrioventricular block cynomolgus monkeys with a cross-over design. Initially, moxifloxacin was intravenously administered in doses of 60 mg/kg/2 h, 60 mg/kg/1 h and 105 mg/kg/1.75 h with an interval of >1 week (n = 3), which provided Cmax of 19.7, 25.4 and 37.8 µg/mL, and induced torsade de pointes in 1, 0 and 3 out of 3 animals, respectively. Next, moxifloxacin was orally administered in doses of 10, 30 and 100 mg/kg with an interval of >1 week (n = 6), which provided Cmax of 1.8, 4.2 and 8.9 µg/mL, and induced torsade de pointes in 0, 0 and 2 out of 6 animals, respectively. A close analysis of pharmacokinetic and electrocardiographic variables indicates that torsade de pointes was induced in animals that had experienced larger systemic exposure of moxifloxacin and/or greater peak QTcF, although Cmax by itself did not necessarily reflect the incidence of torsade de pointes when its administration route was different. These findings may provide a basic guide how to use moxifloxacin in safe for patients with labile repolarization process.


Asunto(s)
Bloqueo Atrioventricular/tratamiento farmacológico , Moxifloxacino/administración & dosificación , Moxifloxacino/efectos adversos , Torsades de Pointes/inducido químicamente , Administración Oral , Animales , Estudios Cruzados , Electrocardiografía , Infusiones Intravenosas , Macaca fascicularis , Moxifloxacino/farmacocinética , Moxifloxacino/farmacología
13.
Pediatr Infect Dis J ; 39(8): e183-e184, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32195773

RESUMEN

A female infant underwent myelomeningocele repair and developed persistent ventricular dilatation. Cerebrospinal fluid (CSF) indices demonstrated meningitis with cultures growing Mycoplasma hominis. The infant was treated with multiple antibiotics including moxifloxacin. Moxifloxacin CSF levels were obtained for pharmacokinetic analysis. This case report adds the importance of understanding the pharmacokinetics of CSF moxifloxacin levels among infants.


Asunto(s)
Antibacterianos/líquido cefalorraquídeo , Antibacterianos/farmacocinética , Meningitis/tratamiento farmacológico , Moxifloxacino/líquido cefalorraquídeo , Moxifloxacino/farmacocinética , Infecciones por Mycoplasma/tratamiento farmacológico , Administración Intravenosa , Antibacterianos/uso terapéutico , Femenino , Humanos , Recién Nacido , Meningitis/microbiología , Moxifloxacino/uso terapéutico , Infecciones por Mycoplasma/complicaciones , Mycoplasma hominis/efectos de los fármacos , Resultado del Tratamiento
14.
Pharm Nanotechnol ; 8(2): 133-147, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32167436

RESUMEN

BACKGROUND: Bacterial conjunctivitis is a serious ocular infection if left untreated. It is caused by several species of bacteria like Pseudomonas, Staphylococcus and Mycobacterium. OBJECTIVE: The present investigation explores the development and characterization of moxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL 100 nanosuspension for ocular drug delivery in order to overcome the problems associated with conventional dosage forms. METHODS: The nanosuspension prepared by nanoprecipitation technique showed successful entrapment of both water-soluble drugs in the polymer matrix indicated by their % entrapment efficiencies. RESULTS: Formulations showed a mean particle size <200 nm with narrow size distribution and positive surface charge due to the presence of quaternary ammonium groups of Eudragit RL100. FTIR study revealed compatibility among the components, while a reduction in the crystallinity of formulation was observed in the PXRD study. The release of both the drugs was found to be sustained in nanosuspension as compared to commercial eyedrops. Ex vivo studies showed increased transcorneal permeation of drugs from nanosuspension, where approximately 2.5-fold and 2-fold increase in the permeation was observed for moxifloxacin hydrochloride and ketorolac tromethamine, respectively. The formulation was stable at 4°C and room temperature. CONCLUSION: Due to their sustained release, positive surface charge and higher transcorneal permeation, this will be a promising ocular drug delivery.


Asunto(s)
Resinas Acrílicas/química , Antibacterianos/farmacocinética , Córnea/química , Ketorolaco Trometamina/farmacocinética , Moxifloxacino/farmacocinética , Animales , Antibacterianos/química , Precipitación Química , Composición de Medicamentos , Liberación de Fármacos , Quimioterapia Combinada , Cabras , Ketorolaco Trometamina/química , Moxifloxacino/química , Nanopartículas , Soluciones Oftálmicas , Tamaño de la Partícula
15.
J Vet Pharmacol Ther ; 43(2): 108-114, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32043623

RESUMEN

In this study, the pharmacokinetics of moxifloxacin (5 mg/kg) was determined following a single intravenous administration of moxifloxacin alone and co-administration with diclofenac (2.5 mg/kg) or flunixin meglumine (2.2 mg/kg) in sheep. Six healthy Akkaraman sheep (2 ± 0.3 years and 53.5 ± 5 kg of body weight) were used. A longitudinal design with a 15-day washout period was used in three periods. In the first period, moxifloxacin was administered by an intravenous (IV) injection. In the second and third periods, moxifloxacin was co-administered with IV administration of diclofenac and flunixin meglumine, respectively. The plasma concentration of moxifloxacin was assayed by high-performance liquid chromatography. The pharmacokinetic parameters were calculated using a two-compartment open pharmacokinetic model. Following IV administration of moxifloxacin alone, the mean elimination half-life (t1/2ß ), total body clearance (ClT ), volume of distribution at steady state (Vdss ) and area under the curve (AUC) of moxifloxacin were 2.27 hr, 0.56 L h-1  kg-1 , 1.66 L/kg and 8.91 hr*µg/ml, respectively. While diclofenac and flunixin meglumine significantly increased the t1/2ß and AUC of moxifloxacin, they significantly reduced the ClT and Vdss . These results suggest that anti-inflammatory drugs could increase the therapeutic efficacy of moxifloxacin by altering its pharmacokinetics.


Asunto(s)
Antibacterianos/farmacocinética , Antiinflamatorios no Esteroideos/farmacocinética , Clonixina/análogos & derivados , Diclofenaco/farmacocinética , Moxifloxacino/farmacocinética , Ovinos/metabolismo , Administración Intravenosa/veterinaria , Animales , Antibacterianos/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Cromatografía Líquida de Alta Presión/veterinaria , Clonixina/administración & dosificación , Clonixina/farmacocinética , Diclofenaco/administración & dosificación , Femenino , Estudios Longitudinales , Moxifloxacino/administración & dosificación , Reproducibilidad de los Resultados
17.
J Cataract Refract Surg ; 45(11): 1568-1574, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31706512

RESUMEN

PURPOSE: To create a model of the abatement profiles of the three most commonly employed endophthalmitis prophylaxis intracameral (IC) antibiotics-cefuroxime, vancomycin, and moxifloxacin-to enable comparison of their durations of efficacy against common endophthalmitis pathogens. SETTINGS: Humber River Hospital and The Eye Foundation of Canada, Toronto, Ontario, the University of Toronto, Ontario, and McGill University, Montreal, Quebec, Canada. DESIGN: Literature review, as well as review of our clinical experience with 4797 consecutive cases with IC vancomycin, followed by 9185 consecutive cases with IC moxifloxacin. METHODS: A detailed review of the prophylactic antibiotic literature was performed. Exponential decay models of the selected IC antibiotics were updated from previous work by the study authors with decay constants adjusted to agree with the available published objective data. RESULTS: The graphs generated by the study data demonstrate the relative duration of IC bactericidal activity of moxifloxacin, cefuroxime, and vancomycin. They suggest that at present, IC moxifloxacin, when administered in appropriate doses, is the most effective agent in preventing postoperative endophthalmitis. Unlike vancomycin and cefuroxime, bacterial resistance to moxifloxacin is dose-dependent, and it is overcome in the vast majority of cases with doses that can safely be achieved intracamerally. The graphs can serve as a useful tool to assess the expected efficacy of each antibiotic in reference to local pathogen resistances. CONCLUSION: The model shows IC moxifloxacin, cefuroxime, and vancomycin durations of bactericidal efficacy post-cataract surgery, which correlate well with the published objective data.


Asunto(s)
Antibacterianos/farmacocinética , Humor Acuoso/metabolismo , Cefuroxima/farmacocinética , Modelos Teóricos , Moxifloxacino/farmacocinética , Vancomicina/farmacocinética , Profilaxis Antibiótica , Bacterias/efectos de los fármacos , Extracción de Catarata , Farmacorresistencia Bacteriana , Endoftalmitis/metabolismo , Endoftalmitis/microbiología , Endoftalmitis/prevención & control , Infecciones Bacterianas del Ojo/metabolismo , Infecciones Bacterianas del Ojo/microbiología , Infecciones Bacterianas del Ojo/prevención & control , Humanos , Pruebas de Sensibilidad Microbiana
18.
Clin Ther ; 41(11): 2204-2218, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31564512

RESUMEN

PURPOSE: Celecoxib is a selective cyclooxygenase-2 inhibitor widely used in patients with osteoarthritis and rheumatoid arthritis. Recently, nonclinical data on the inhibition of human ether-à-go-go-related gene potassium channels by celecoxib were reported, but there is no compelling evidence for this finding in humans. The aim of this study was to assess the potential effects of celecoxib on cardiac repolarization by conducting a thorough QT study, which was designed in compliance with the related guidelines. METHODS: This randomized, open-label, positive- and negative-controlled, crossover clinical study was conducted in healthy male and female subjects. Each subject received, in 1 of 4 randomly assigned sequences, all of the following 3 interventions: celecoxib 400 mg once daily for 6 days; a single dose of moxifloxacin 400 mg, which served as a positive control to assess the assay sensitivity; and water without any drug, which served as a negative control. Serial 12-lead ECG and blood samples for pharmacokinetic analysis were collected periodically over 24 h. Individually RR-corrected QT intervals (QTcI) and Fridericia method-corrected QT intervals (QTcF) were calculated and evaluated. FINDINGS: Twenty-eight subjects were allocated to 1 of the 4 intervention sequences. The largest time-matched mean effects of celecoxib on the QTcI and QTcF were <5 ms, and the upper bounds of the 1-sided 95% CIs of those values did not exceed 10 ms. Moreover, none of the subjects had an absolute QTcI value of >450 ms or a change from baseline in QTcI of >60 ms after multiple administrations of celecoxib. The QTcI did not show a positive correlation with celecoxib concentrations in the range up to ~2700 µg/L. The overall effects of moxifloxacin on the QTcI and QTcF were enough to establish assay sensitivity. No serious adverse events were reported, with a total of 11 AEs reported in 8 subjects. IMPLICATIONS: Celecoxib caused no clinically relevant increase in the QT/QTc interval at the maximum dose level used in current practice settings. ClinicalTrials.gov identifier: NCT03822520.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Celecoxib/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Adulto , Antiinflamatorios no Esteroideos/sangre , Antiinflamatorios no Esteroideos/farmacocinética , Celecoxib/sangre , Celecoxib/farmacocinética , Estudios Cruzados , Método Doble Ciego , Electrocardiografía/efectos de los fármacos , Femenino , Humanos , Masculino , Moxifloxacino/sangre , Moxifloxacino/farmacocinética , Moxifloxacino/farmacología , Adulto Joven
19.
J Nanobiotechnology ; 17(1): 103, 2019 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-31581948

RESUMEN

BACKGROUND: Immunocompromised individuals and those with lung dysfunction readily acquire pulmonary bacterial infections, which may cause serious diseases and carry a heavy economic burden. Maintaining adequate antibiotic concentrations in the infected tissues is necessary to eradicate resident bacteria. To specifically deliver therapeutics to the infected pulmonary tissues and enable controlled release of payloads at the infection site, a ROS-responsive material, i.e. 4-(hydroxymethyl) phenylboronic acid pinacol ester-modified α-cyclodextrin (Oxi-αCD), was employed to encapsulate moxifloxacin (MXF), generating ROS-responsive MXF-containing nanoparticles (MXF/Oxi-αCD NPs). RESULTS: MXF/Oxi-αCD NPs were coated with DSPE-PEG and DSPE-PEG-folic acid, facilitating penetration of the sputum secreted by the infected lung and enabling the active targeting of macrophages in the inflammatory tissues. In vitro drug release experiments indicated that MXF release from Oxi-αCD NPs was accelerated in the presence of 0.5 mM H2O2. In vitro assay with Pseudomonas aeruginosa demonstrated that MXF/Oxi-αCD NPs exhibited higher antibacterial activity than MXF. In vitro cellular study also indicated that folic acid-modified MXF/Oxi-αCD NPs could be effectively internalized by bacteria-infected macrophages, thereby significantly eradicating resident bacteria in macrophages compared to non-targeted MXF/Oxi-αCD NPs. In a mouse model of pulmonary P. aeruginosa infection, folic acid-modified MXF/Oxi-αCD NPs showed better antibacterial efficacy than MXF and non-targeted MXF/Oxi-αCD NPs. Meanwhile, the survival time of mice was prolonged by treatment with targeting MXF/Oxi-αCD NPs. CONCLUSIONS: Our work provides a strategy to overcome the mucus barrier, control drug release, and improve the targeting capability of NPs for the treatment of pulmonary bacterial infections.


Asunto(s)
Antibacterianos/administración & dosificación , Ciclodextrinas/metabolismo , Preparaciones de Acción Retardada/metabolismo , Moxifloxacino/administración & dosificación , Neumonía Bacteriana/tratamiento farmacológico , Especies Reactivas de Oxígeno/metabolismo , Células A549 , Animales , Antibacterianos/farmacocinética , Antibacterianos/uso terapéutico , Ciclodextrinas/química , Preparaciones de Acción Retardada/química , Sistemas de Liberación de Medicamentos , Femenino , Humanos , Pulmón/metabolismo , Pulmón/microbiología , Ratones , Moxifloxacino/farmacocinética , Moxifloxacino/uso terapéutico , Nanopartículas/química , Nanopartículas/metabolismo , Neumonía Bacteriana/metabolismo , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/metabolismo , Pseudomonas aeruginosa/efectos de los fármacos , Células RAW 264.7
20.
Artículo en Inglés | MEDLINE | ID: mdl-31611354

RESUMEN

Clinical studies of new antitubercular drugs are costly and time-consuming. Owing to the extensive tuberculosis (TB) treatment periods, the ability to identify drug candidates based on their predicted clinical efficacy is vital to accelerate the pipeline of new therapies. Recent failures of preclinical models in predicting the activity of fluoroquinolones underline the importance of developing new and more robust predictive tools that will optimize the design of future trials. Here, we used high-content imaging screening and pharmacodynamic intracellular (PDi) modeling to identify and prioritize fluoroquinolones for TB treatment. In a set of studies designed to validate this approach, we show moxifloxacin to be the most effective fluoroquinolone, and PDi modeling-based Monte Carlo simulations accurately predict negative culture conversion (sputum sterilization) rates compared to eight independent clinical trials. In addition, PDi-based simulations were used to predict the risk of relapse. Our analyses show that the duration of treatment following culture conversion can be used to predict the relapse rate. These data further support that PDi-based modeling offers a much-needed decision-making tool for the TB drug development pipeline.


Asunto(s)
Antituberculosos/farmacología , Antituberculosos/farmacocinética , Fluoroquinolonas/farmacología , Fluoroquinolonas/farmacocinética , Modelos Biológicos , Tuberculosis Pulmonar/tratamiento farmacológico , Tuberculosis Pulmonar/metabolismo , Línea Celular , Simulación por Computador , Técnicas de Apoyo para la Decisión , Desarrollo de Medicamentos , Humanos , Macrófagos/efectos de los fármacos , Macrófagos/microbiología , Método de Montecarlo , Moxifloxacino/farmacocinética , Moxifloxacino/farmacología , Mycobacterium tuberculosis/efectos de los fármacos , Células THP-1 , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...